Investigational treatment options in microscopic colitis
Standard
Investigational treatment options in microscopic colitis. / Madisch, Ahmed; Morgner, Andrea; Stolte, Manfred; Miehlke, Stephan.
In: EXPERT OPIN INV DRUG, Vol. 17, No. 12, 12.2008, p. 1829-37.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Investigational treatment options in microscopic colitis
AU - Madisch, Ahmed
AU - Morgner, Andrea
AU - Stolte, Manfred
AU - Miehlke, Stephan
PY - 2008/12
Y1 - 2008/12
N2 - Collagenous and lymphocytic colitis are the two recognized major presentations of microscopic colitis. Both diseases present with chronic watery diarrhea and a chronic inflammatory infiltrate in the colonic mucosa without specific endoscopic abnormalities, and hence diagnosis is established by histology. Recent epidemiological studies suggest that microscopic colitis may affect as many patients as Crohn's disease or ulcerative colitis. The cause of these diseases is unknown; however, several lines of evidence support the hypothesis of mucosal injury from an unknown agent in the fecal stream. Due to the lack of disease causality, therapeutic management of microscopic colitis is now directed primarily at symptoms' resolution or improvement. Based on current evidence, oral budesonide represents an effective treatment option for patients with microscopic colitis to achieve and maintain remission. Other anti-inflammatory drugs such as mesalazine or bismuth subsalicylate are now under evaluation. The optimal long-term management strategy of microscopic colitis, however, remains an unsolved issue.
AB - Collagenous and lymphocytic colitis are the two recognized major presentations of microscopic colitis. Both diseases present with chronic watery diarrhea and a chronic inflammatory infiltrate in the colonic mucosa without specific endoscopic abnormalities, and hence diagnosis is established by histology. Recent epidemiological studies suggest that microscopic colitis may affect as many patients as Crohn's disease or ulcerative colitis. The cause of these diseases is unknown; however, several lines of evidence support the hypothesis of mucosal injury from an unknown agent in the fecal stream. Due to the lack of disease causality, therapeutic management of microscopic colitis is now directed primarily at symptoms' resolution or improvement. Based on current evidence, oral budesonide represents an effective treatment option for patients with microscopic colitis to achieve and maintain remission. Other anti-inflammatory drugs such as mesalazine or bismuth subsalicylate are now under evaluation. The optimal long-term management strategy of microscopic colitis, however, remains an unsolved issue.
KW - Adrenal Cortex Hormones
KW - Animals
KW - Colitis
KW - Humans
KW - Probiotics
KW - Quality of Life
KW - Randomized Controlled Trials as Topic
KW - Journal Article
KW - Review
U2 - 10.1517/13543780802514500
DO - 10.1517/13543780802514500
M3 - SCORING: Journal article
C2 - 19012499
VL - 17
SP - 1829
EP - 1837
JO - EXPERT OPIN INV DRUG
JF - EXPERT OPIN INV DRUG
SN - 1354-3784
IS - 12
ER -